At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 11 enrolled
Drug / intervention
SBC-103drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Open Label Study in MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously
In Brief
A Phase 2 clinical trial evaluating SBC-103 for Mucopolysaccharidosis IIIB. Completed, enrolled 11 participants across 4 sites in 3 countries.
Detailed Summary
Study to evaluate the safety and tolerability of intravenous (IV) administration of SBC-103 in participants with mucopolysaccharidosis III, type B (MPS IIIB, Sanfilippo B) with evaluable signs or symptoms of developmental delay.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMucopolysaccharidosis IIIB
CountriesSpain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartJan 2015
Primary CompletionOct 2017
TodayJul 2026
First PostedDec 24, 2014
Enrollment StartJan 22, 2015
Primary CompletionOct 16, 2017
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 11.5 years ago
Interventions
SBC-103drug